2019 About APS EB 2019 Information

Tang Prize Award

Lecture — Saturday, April 6, 2019 — 6:00 PM - 7:00 PM — Convention Center, Room
Tang Foundation — Chair: Brian Druker — Co-Chair:

Abl is a tyrosine kinase, the gene of which upon translocation to a different chromosomal site (Bcr [breakpoint cluster region]) becomes constitutively active. In addition to Abl, Gleevec also inhibits Kit, PDGF and other tyrosine kinase oncoproteins. It has been useful in the treatment of acute lymphocytic leukemia (ALL) and certain types of gastrointestinal stromal tumors (GISTs) where Kit is overexpressed. Now there are more than 29 TKIs which have been approved for clinical use. Clearly, Dr. Druker’s first successful trials heralded this still burgeoning targeted therapy era. Dr. Druker was also involved in the development of the 4G10 antibody (at Thomas Robert’s lab) which recognizes phosphotyrosine and was used by Novartis colleagues in the screening of Gleevec. Thus, Dr. Druker’s contributions are in both the development and application of Gleevec, which was the first successful example of tyrosine kinase-targeted therapy by small molecule inhibitors.


  • Imatinib as a Paradigm of Targeted Cancer Therapies
    Brian Druker — Knight Cancer Inst., Oregon Hlth. & Sci. Univ.

Host Societies

Experimental Biology is the annual meeting of five Host Societies. By becoming a member of one of the societies below before registering, you can save up to $200 off the price of regular registration. Click a Host Society logo below to join today and save:

Copyright © Experimental Biology (EB) | Experimental Biology® is a federally registered trademark of EB.